Literature DB >> 18850008

An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation.

F Talotta1, A Cimmino, M R Matarazzo, L Casalino, G De Vita, M D'Esposito, R Di Lauro, P Verde.   

Abstract

The transcription factor AP-1 plays key roles in tumorigenesis, by regulating a variety of protein-coding genes, implicated in multiple hallmarks of cancer. Among non-coding genes, no AP-1 target has been described yet in tumorigenesis. MicroRNAs (miRNAs) are negative post-transcriptional regulators of protein-coding genes. miRNA expression signatures are highly relevant in cancer and several tumor-associated miRNAs (oncomirs) play critical roles in oncogenesis. Here, we show that the miRNA miR-21, which represents the most frequently upregulated oncomir in solid tumors, is induced by AP-1 in response to RAS. By analyzing validated miR-21 targets, we have found that the tumor suppressors PTEN and PDCD4 are downregulated by RAS in an AP-1- and miR-21-dependent fashion. We further show that, given the role of PDCD4 as negative regulator of AP-1, the miR-21-mediated downregulation of PDCD4 is essential for the maximal induction of AP-1 activity in response to RAS. Our data reveal a novel mechanism of positive autoregulation of the AP-1 complex in RAS transformation and disclose the function of oncomirs as critical targets and regulators of AP-1 in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18850008     DOI: 10.1038/onc.2008.370

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  118 in total

1.  PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.

Authors:  Kenji Zennami; Su Mi Choi; Ross Liao; Ying Li; Wikum Dinalankara; Luigi Marchionni; Fatema H Rafiqi; Akira Kurozumi; Koji Hatano; Shawn E Lupold
Journal:  Mol Cancer Res       Date:  2018-12-05       Impact factor: 5.852

2.  Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo.

Authors:  Arti B Gaur; Susan L Holbeck; Nancy H Colburn; Mark A Israel
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

3.  Global expression analysis identified a preferentially nerve growth factor-induced transcriptional program regulated by sustained mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) and AP-1 protein activation during PC12 cell differentiation.

Authors:  Steven Mullenbrock; Janki Shah; Geoffrey M Cooper
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

Review 4.  Have tumor suppressor PDCD4 and its counteragent oncogenic miR-21 gone rogue?

Authors:  Matthew R Young; Arti N Santhanam; Noriko Yoshikawa; Nancy H Colburn
Journal:  Mol Interv       Date:  2010-04

5.  Spaceflight alters expression of microRNA during T-cell activation.

Authors:  Millie Hughes-Fulford; Tammy T Chang; Emily M Martinez; Chai-Fei Li
Journal:  FASEB J       Date:  2015-08-14       Impact factor: 5.191

6.  Cloning and identification of microRNAs in bovine alveolar macrophages.

Authors:  Guangxian Xu; Yan Zhang; Hao Jia; Juan Li; Xiaoming Liu; John F Engelhardt; Yujiong Wang
Journal:  Mol Cell Biochem       Date:  2009-06-09       Impact factor: 3.396

7.  TRIM65 regulates microRNA activity by ubiquitination of TNRC6.

Authors:  Shitao Li; Lingyan Wang; Bishi Fu; Michael A Berman; Alos Diallo; Martin E Dorf
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

Review 8.  MicroRNA-21 in the pathogenesis of acute kidney injury.

Authors:  Ya-Feng Li; Ying Jing; Jielu Hao; Nathan C Frankfort; Xiaoshuang Zhou; Bing Shen; Xinyan Liu; Lihua Wang; Rongshan Li
Journal:  Protein Cell       Date:  2013-11-10       Impact factor: 14.870

9.  Trim65: a cofactor for regulation of the microRNA pathway.

Authors:  Shitao Li; Lingyan Wang; Bishi Fu; Martin E Dorf
Journal:  RNA Biol       Date:  2014       Impact factor: 4.652

10.  microRNA Regulation and Its Consequences in Cancer.

Authors:  Sonya Parpart; Xin Wei Wang
Journal:  Curr Pathobiol Rep       Date:  2012-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.